ES8504461A1 - Un procedimiento para obtener un polidoma. - Google Patents
Un procedimiento para obtener un polidoma.Info
- Publication number
- ES8504461A1 ES8504461A1 ES521370A ES521370A ES8504461A1 ES 8504461 A1 ES8504461 A1 ES 8504461A1 ES 521370 A ES521370 A ES 521370A ES 521370 A ES521370 A ES 521370A ES 8504461 A1 ES8504461 A1 ES 8504461A1
- Authority
- ES
- Spain
- Prior art keywords
- antibodies
- preparation
- uses therefor
- polydomas
- target antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000009977 dual effect Effects 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000004408 hybridoma Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Abstract
PROCEDIMIENTO PARA OBTENER UN POLIDOMA.CONSISTE EN FUSIONAR UN HIBRIDOMA QUE PRODUCE UN ANTICUERPO MONOCLONAL CONTRA UN PRIMER DETERMINANTE ANTIGENICO CON UN LINFOCITO B QUE SEGREGA UN ANTICUERPO MONOCLONAL CONTRA UN SEGUNDO DETERMINANTE ANTIGENICO EN PRESENCIA DE UN AGENTE PROMOTOR DE LA FUSION. EL HIBRIDOMA ES SOMETIDO A RETRO-SELECCION QUE SE REALIZA POR CULTIVO DE CELULAS DE HIBRIDOMA EN UN MEDIO QUE COMPRENDE UN MIEMBRO DEL GRUPO CONSTITUIDO POR 8-AZAGUANINA, 6-TIOGUANINA, 5-BROMOURACIL-DESOXIRRIBOSA O 2-AMINOPURINA, CON LO QUE SE OBTIENEN CELULAS DE HIBRIDOMA SENSIBLES A UN MEDIO QUE CONTIENE HIPOXANTINA-AMINOPTERINA-TIMIDINA.TIENE APLICACION COMO ANTICUERPOS CON ESPECIFICACIONES DUALES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36778482A | 1982-04-12 | 1982-04-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES8504461A1 true ES8504461A1 (es) | 1985-04-16 |
ES521370A0 ES521370A0 (es) | 1985-04-16 |
Family
ID=23448582
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES521370A Granted ES521370A0 (es) | 1982-04-12 | 1983-04-11 | Un procedimiento para obtener un polidoma. |
ES527963A Granted ES527963A0 (es) | 1982-04-12 | 1983-12-12 | Un procedimiento de inmunoensayo |
ES533931A Expired ES8506091A1 (es) | 1982-04-12 | 1984-07-02 | Un procedimiento para obtener un polidoma |
ES533930A Granted ES533930A0 (es) | 1982-04-12 | 1984-07-02 | Un procedimiento para obtener un polidoma |
ES537257A Expired ES8606655A1 (es) | 1982-04-12 | 1984-10-31 | Un procedimiento de inmunoensayo |
ES538727A Expired ES8604424A1 (es) | 1982-04-12 | 1984-12-18 | Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983 |
ES545247A Expired ES8607386A1 (es) | 1982-04-12 | 1985-07-16 | Un procedimiento para obtener un polidoma |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES527963A Granted ES527963A0 (es) | 1982-04-12 | 1983-12-12 | Un procedimiento de inmunoensayo |
ES533931A Expired ES8506091A1 (es) | 1982-04-12 | 1984-07-02 | Un procedimiento para obtener un polidoma |
ES533930A Granted ES533930A0 (es) | 1982-04-12 | 1984-07-02 | Un procedimiento para obtener un polidoma |
ES537257A Expired ES8606655A1 (es) | 1982-04-12 | 1984-10-31 | Un procedimiento de inmunoensayo |
ES538727A Expired ES8604424A1 (es) | 1982-04-12 | 1984-12-18 | Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983 |
ES545247A Expired ES8607386A1 (es) | 1982-04-12 | 1985-07-16 | Un procedimiento para obtener un polidoma |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0105360A4 (es) |
JP (2) | JPH0753119B2 (es) |
AT (1) | AT394577B (es) |
AU (1) | AU550486B2 (es) |
CA (1) | CA1213229A (es) |
CH (1) | CH672796A5 (es) |
ES (7) | ES521370A0 (es) |
FI (1) | FI834529A (es) |
GB (4) | GB2128631B (es) |
IT (1) | IT1219778B (es) |
WO (1) | WO1983003679A1 (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3177776B2 (ja) * | 1988-09-27 | 2001-06-18 | 武田薬品工業株式会社 | ハイブリッドモノクローナル抗体,抗体産生ポリドーマおよび抗体含有薬剤 |
US5292668A (en) * | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
CA1214123A (en) * | 1983-01-20 | 1986-11-18 | Masashi Matsui | Cell lines for use in the preparation of hybridoma cells |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
EP0467416A1 (en) * | 1983-09-01 | 1992-01-22 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
ATE64622T1 (de) * | 1984-04-23 | 1991-07-15 | Boston Biomed Res Inst | Doppelspezifische antikoerper-determinanten. |
NL8501219A (nl) * | 1985-04-29 | 1986-11-17 | Stichting Vrienden Van De Stic | Immunologisch complex, de bereiding en toepassing daarvan. |
WO1987006240A1 (en) | 1986-04-14 | 1987-10-22 | The General Hospital Corporation | Heterobifunctional antibodies and method of use |
US5453269A (en) * | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
FR2604092B1 (fr) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
GB8626412D0 (en) * | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
GB8626413D0 (en) * | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
US5053226A (en) * | 1987-07-15 | 1991-10-01 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
EP0308936B1 (en) * | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
GB2218100A (en) * | 1988-03-02 | 1989-11-08 | Erling Sundrehagen | Conjugates for the detection and/or quantification of antigenic substances in body fluids |
US4892824A (en) * | 1988-03-15 | 1990-01-09 | Synbiotics Corporation | Fast track method for producing monoclonal bi-specific immunoglobulins |
US5582862A (en) * | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
US5372812A (en) * | 1988-04-04 | 1994-12-13 | The General Hospital Corporation | Composition and method for acceleration of clot lysis |
JPH02196799A (ja) * | 1988-04-08 | 1990-08-03 | Agency Of Ind Science & Technol | 抗ヒト癌蛋白複合体 |
US5851527A (en) * | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
IT1235349B (it) * | 1988-12-23 | 1992-06-30 | Biodata Spa | Saggio immunologico per determinazioni in fase omogenea |
US5217713A (en) * | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
CA2006408A1 (en) * | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
WO1990012109A1 (en) * | 1989-03-30 | 1990-10-18 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
FR2652004B1 (fr) * | 1989-09-21 | 1994-10-28 | Immunotech Partners | Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques. |
DE69130561T2 (de) * | 1990-02-16 | 1999-06-24 | Boston Biomed Res Inst | Hybride Reagenzien mit der Fähigkeit, Moleküle selektiv in Zellen freizusetzen |
TW212184B (es) * | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
WO1992019973A1 (en) * | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
GB9316369D0 (en) * | 1993-08-06 | 1993-09-22 | Surface Active Ltd | Diagnostic method |
US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
GB9421468D0 (en) * | 1994-10-18 | 1994-12-07 | Surface Active Ltd | Biosensor |
EP0937146A2 (en) * | 1996-09-20 | 1999-08-25 | The General Hospital Corporation | Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin |
US20020132274A1 (en) | 2001-01-17 | 2002-09-19 | Nevalainen Marja T. | Diagnostic and monitorings methods for cancer |
ES2556641T3 (es) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
JP4918476B2 (ja) | 2004-03-16 | 2012-04-18 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性疾患を治療するための置換フェノキシ−及びフェニルチオ−誘導体 |
JP2008519863A (ja) | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | N末端にアミノ安息香酸単位を有するオーリスタチン |
ES2477765T3 (es) | 2005-04-19 | 2014-07-17 | Seattle Genetics, Inc. | Agentes de unión al anti-cd70 humanizado y usos de los mismos |
SI3248613T1 (sl) | 2005-07-18 | 2022-04-29 | Seagen Inc. | Konjugati beta-glukuronidni linker-zdravilo |
US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
NZ577933A (en) | 2007-01-22 | 2011-12-22 | Genentech Inc | Polyelectrolyte precipitation and purification of antibodies |
CN102076865B (zh) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
CA2906784C (en) | 2013-03-15 | 2023-02-28 | The Centre For Drug Research And Development | Cytotoxic and anti-mitotic compounds, and methods of using the same |
WO2015053381A1 (ja) * | 2013-10-10 | 2015-04-16 | 幸成 加藤 | 抗ポドプラニン抗体 |
CN106255513B (zh) | 2013-12-27 | 2022-01-14 | 酵活有限公司 | 用于药物偶联物的含磺酰胺连接系统 |
RU2723651C2 (ru) | 2014-09-17 | 2020-06-17 | Займворкс Инк. | Цитотоксические и антимитотические соединения и способы их применения |
JP6412906B2 (ja) | 2015-11-03 | 2018-10-24 | 財團法人工業技術研究院Industrial Technology Research Institute | 化合物、リンカー−薬物およびリガンド−薬物複合体 |
UA125510C2 (uk) | 2016-03-25 | 2022-04-13 | Сіджен Інк. | Спосіб отримання пегильованої сполуки лікарський препарат-лінкер, де лікарським препаратом є ауристатин, та її проміжних сполук |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
EP3600443A1 (en) | 2017-03-24 | 2020-02-05 | Seattle Genetics, Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
EP3847195A4 (en) * | 2018-08-30 | 2022-09-07 | Innovative Cellular Therapeutics Holdings, Ltd. | CHEMERA ANTIGEN RECEPTOR CELLS FOR SOLID TUMOR TREATMENT |
SG11202112223XA (en) | 2019-05-10 | 2021-12-30 | Takeda Pharmaceuticals Co | Antibody drug conjugates |
TW202138388A (zh) | 2019-12-30 | 2021-10-16 | 美商西根公司 | 以非海藻糖苷化抗-cd70抗體治療癌症之方法 |
IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
KR20240025597A (ko) | 2021-06-29 | 2024-02-27 | 씨젠 인크. | 비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4130634A (en) * | 1974-03-15 | 1978-12-19 | University Of Illinois Foundation | Method for detecting and quantifying antigens |
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
-
1983
- 1983-04-11 ES ES521370A patent/ES521370A0/es active Granted
- 1983-04-11 CA CA000425558A patent/CA1213229A/en not_active Expired
- 1983-04-12 WO PCT/US1983/000525 patent/WO1983003679A1/en not_active Application Discontinuation
- 1983-04-12 IT IT20548/83A patent/IT1219778B/it active
- 1983-04-12 AU AU15559/83A patent/AU550486B2/en not_active Expired
- 1983-04-12 GB GB08332646A patent/GB2128631B/en not_active Expired
- 1983-04-12 CH CH6700/83A patent/CH672796A5/de not_active IP Right Cessation
- 1983-04-12 EP EP19830901672 patent/EP0105360A4/en not_active Ceased
- 1983-04-12 AT AT0901883A patent/AT394577B/de not_active IP Right Cessation
- 1983-12-09 FI FI834529A patent/FI834529A/fi not_active Application Discontinuation
- 1983-12-12 ES ES527963A patent/ES527963A0/es active Granted
-
1984
- 1984-07-02 ES ES533931A patent/ES8506091A1/es not_active Expired
- 1984-07-02 ES ES533930A patent/ES533930A0/es active Granted
- 1984-10-31 ES ES537257A patent/ES8606655A1/es not_active Expired
- 1984-12-18 ES ES538727A patent/ES8604424A1/es not_active Expired
-
1985
- 1985-07-16 ES ES545247A patent/ES8607386A1/es not_active Expired
- 1985-12-09 GB GB08530310A patent/GB2167086B/en not_active Expired
- 1985-12-09 GB GB08530308A patent/GB2168998B/en not_active Expired
- 1985-12-09 GB GB08530309A patent/GB2169921B/en not_active Expired
-
1987
- 1987-01-05 JP JP62000342A patent/JPH0753119B2/ja not_active Expired - Lifetime
-
1994
- 1994-02-10 JP JP6016728A patent/JP2562002B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES8604424A1 (es) | Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983 | |
JPS6447378A (en) | Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof | |
JPS6413988A (en) | Hybridoma | |
DK450183D0 (da) | Humane monoklone antistoffer mod et bakterietoksin samt disses fremstilling, kontinuerlige cellelinier, som producerer antitoksinantistoffer, samt antistoffernes anvendelser | |
IL80231A (en) | Monoclonal anti-human breast cancer antibodies and hybridomas producing them,and diagnosis of human breast tumors | |
ZA833686B (en) | Human human hybridomas for cervical carcinoma | |
PH16642A (en) | Complement-fixing monoclonal antibody to human t cells,and methods of preparing same | |
IE800565L (en) | Monoclonal antibodies to human t cells | |
EP0419574A4 (en) | Monoclonal antibodies to the light chain region of human factor xii and methods of preparing and using the same | |
DE3070744D1 (en) | Hybrid cell line for producing complement-fixing, monoclonal antibody to human suppressor t cells, antibody, method of preparation of this antibody, diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody | |
DE3485432D1 (de) | Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene. | |
EP0212403A3 (en) | Monoclonal antibodies to mucin-like human differentiation antigens | |
AU6496180A (en) | Hybridoma for producing monoclonal antibodies | |
AU545222B2 (en) | Hybridoma for producing monoconal antibodies | |
GB8609058D0 (en) | Monoclonal antibodies | |
EP0351045A3 (en) | Monoclonal antibody nuh2 capable of inactivating motility of sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen | |
ES2000615A6 (es) | Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3" | |
GR3020387T3 (en) | Ctaa 28a32, the antigen recognized by mca 28a32 | |
ES8401982A1 (es) | "procedimiento de preparacion de globulina antilinfocitaria t". | |
EP0089771A3 (en) | Atcc hb8116 and its monoclonal anti-h-y antibody, hyclonalan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD1A | Patent lapsed |
Effective date: 19970401 |